Press Releases

Press Releases

February 7, 2019
WOBURN, Mass. , Feb. 07, 2019 (GLOBE NEWSWIRE) -- Replimune Group Inc. (NASDAQ: REPL), a biotechnology company developing oncolytic immunotherapies derived from its Immulytic™ platform, today announced that Robert Coffin , Ph.D., Chief Executive Officer and Director of Replimune , will participate